APA

Stallmach A., Langbein C., Atreya R., Bruns T., Dignass A., Ende K., Hampe J., Hartmann F., Neurath M. F., Maul J., Preiss J. C., Schmelz R., Siegmund B., Schulze H., Teich N., von Arnim U., Baumgart D. C. & Schmidt C. (20170818). Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. : Alimentary pharmacology & therapeutics.

Chicago

Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath M F, Maul J, Preiss J C, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart D C and Schmidt C. 20170818. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. : Alimentary pharmacology & therapeutics.

Harvard

Stallmach A., Langbein C., Atreya R., Bruns T., Dignass A., Ende K., Hampe J., Hartmann F., Neurath M. F., Maul J., Preiss J. C., Schmelz R., Siegmund B., Schulze H., Teich N., von Arnim U., Baumgart D. C. and Schmidt C. (20170818). Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. : Alimentary pharmacology & therapeutics.

MLA

Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath M F, Maul J, Preiss J C, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart D C and Schmidt C. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. : Alimentary pharmacology & therapeutics. 20170818.